Vincent graduated with a MSc degree in Medical Biology from the University of Amsterdam, where he also obtained a PhD in Biochemistry. His doctoral research focused on the phospholipid flippase ATP8B1 and its role in intracellular trafficking. This work resulted in three first-authored experimental publications in highly-ranked scientific journals.
Following this Vincent continued to work in academia as a post-doctoral researcher in the Academic Medical Center in Amsterdam. Using direct input from the pharmaceutical industry he developed and studied several cell culture systems that can act as models for drug metabolism and toxicity testing. He also became the main inventor on a patent application for a new improved liver cell line with potential use in a bio-artificial liver system.
Vincent went on to work as an analyst in the Healthcare team of M Ventures, the corporate venture capital arm of Merck KGaA, where he performed due diligence on technical, commercial and patented features of new investment proposals in the fields of (immuno-)oncology and immunology.
Prior to joining HGF, Vincent worked in the technology transfer office of the University of Leiden, specifically at the Leiden University Medical Center. Here, his roles included scouting for new (patentable) inventions, IP management, business development, advising on start-ups and investments, licencing and research agreements. During this time he came into contact with many cutting-edge technologies in the field of medical devices, diagnostic methods, software applications, antibodies, and cancer neoepitopes.
At HGF Vincent gained ample experience with patenting agrochemicals and various other subjects that combine chemistry and biology.
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
HGF Partner Dr Susan Keston and Senior Patent Attorney Dr Sofie McPherson will be presenting a webinar ‘How to capitalise on the 5G healthcare revolution’ on 25th May. This session will explore how 5G …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.